Drugs / TQB2930
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05380882 | May 2022 → Apr 2023 | cancer of unknown primary site | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT07653685 | Jul 2026 → Jun 2027 expected | colorectal cancer | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07512583 | May 2026 → Mar 2028 expected | neoplasm | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06202261 | Apr 2023 → Dec 2026 expected | breast carcinoma | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07047365 | Jul 2025 → Jun 2028 expected | HER2 positive breast carcinoma | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TQB2930 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07047365 ↗ |
| Action | Inhibit | “leading to a dual HER2 signal blockage” NCT05380882 ↗ |
| Route | Intravenous | “intravenous infusion of TQB2930 injection” NCT05380882 ↗ |